RESUMEN
Despite universal immunization coverage on a global scale among children, the vast majority of immunocompromised adults, and particularly the elderly, remain unvaccinated. Considering that a significant proportion of mortality from pneumococcal disease occurs among the elderly, preventive measures through pneumococcal vaccination in adults, especially the elderly with co-morbidities, needs to be urgently explored and implemented in Africa, and particularly in Nigeria, to stem the tide of deaths resulting from pneumococcal disease among this population. This article looks at the pneumococcal epidemiology and burden of disease in Nigeria, as well as the vaccines available and the rationale for adult pneumococcal vaccination. It also highlights the potential barriers to use and makes recommendations to overcome these barriers and improve acceptance in Nigeria.
Malgré une couverture vaccinale universelle à l'échelle mondiale chez les enfants, la grande majorité des adultes immunodéprimés, et particulièrement les personnes âgées, ne sont toujours pas vaccinés. Considérant qu'une proportion significative de la mortalité due aux maladies pneumococciques se produit chez les personnes âgées, les mesures préventives par la vaccination antipneumococcique chez les adultes, en particulier les personnes âgées, sont essentielles. pneumococcique chez les adultes, en particulier les personnes âgées souffrant de comorbidité, doivent être doivent être explorées et mises en Åuvre de toute urgence en Afrique, et en particulier au Nigeria, afin d'endiguer la vague de mortalité due aux infections à pneumocoques. Nigéria, afin d'endiguer le nombre de décès dus aux infections à pneumocoques dans cette population. Cet article examine l'épidémiologie du pneumocoque pneumococcique et la charge de morbidité au Nigeria, ainsi que les vaccins disponibles et la raison d'être de la vaccination antipneumococcique des adultes. Il met également Il met également en évidence les obstacles potentiels à l'utilisation de ce vaccin et formule des recommandations pour les surmonter et améliorer son acceptation au Nigeria. recommandations pour surmonter ces obstacles et améliorer l'acceptation du vaccin au Nigeria.
Asunto(s)
Infecciones Neumocócicas , Vacunas Neumococicas , Adulto , Anciano , Niño , Humanos , Nigeria/epidemiología , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/prevención & control , VacunaciónRESUMEN
BACKGROUND: Assessment of health related quality of life (HRQL) has become central to assessing the self-perceived impact of physical and mental impairment on patient's health. Studies have reported a high rate of psychological disturbances among asthmatics; however, the impact of these psychological factors on HRQL remains unexplored. OBJECTIVES: To assess the health related quality of life among a sample of asthmatics and to identify the psychological and clinical variables that affect quality of life among asthmatics. METHOD: A total of 81 patients attending the clinic were assessed using the Mini-Asthma Quality of Life questionnaire (Mini-AQLQ), and the Hospital Anxiety and Depression Scale (HADS). Sociodemographic and clinical variables were also obtained from the patients, the lung function was assessed using Peak Expiratory Flow Rate (PEFR). RESULTS: Mean age of all the patients was 35.22 (SD±14.36) with a mean duration of asthma symptoms of 17.5 (SD±14.4) years. Mean peak expiratory flow was 336 l/min (SD±74.12). Anxiety was present in 44.4% of respondents, while 40% of respondents reported the presence of depressive symptoms, 48.1% of the respondents reported low scores on the asthma quality of life questionnaire. Poor quality of life was associated with the presence of psychological symptoms, female sex, and lower educational level. CONCLUSION: Psychosocial variables are just as important as clinical variables as determinants of health related quality of life among asthmatics.